Bone Care International Announces Changes in Management Team.

Business Editors/Health & Medical Writers

MIDDLETON, Wis.--(BUSINESS WIRE)--June 14, 2002

Bone Care International, Inc. (NASDAQ:BCII), today announced two key changes to the company's management team. Andrew Morgan, R.Ph., has joined the company as Vice President of Regulatory, Quality and Compliance. In addition, Paul Peterson, Vice President of Sales has resigned his position after four years of leadership but will continue as a consultant during this transition.

"Andrew Morgan will provide the required leadership to build a world class Regulatory department." stated Paul Berns, President and CEO. Mr. Morgan previously managed the Regulatory Affairs department for Medeva, Inc., and most recently directed the Regulatory Affairs department at Celltech Pharmaceuticals Inc.

In regard to the sales management transition, Paul Berns stated "I'd like to extend deep gratitude to Paul Peterson for his four years of building the Bone Care sales organization from the ground up. We appreciate the role he has played in the growth and development of Bone Care and wish him all the best. As a company moving forward, we intend to hire a successor who will help drive sales in the business and who will strengthen our foothold in the Vitamin D marketplace. The current leadership team is ready to take Bone Care to the next level of performance." A search is being initiated to replace Mr. Peterson.

Bone Care is a pharmaceutical company engaged in discovering, developing and commercializing improved vitamin D-hormone therapies to treat secondary hyperparathyroidism in patients with kidney, or renal disease, and osteoporosis, and other diseases including psoriasis and cancers of the prostate, breast and colon.

This press release contains forward-looking statements. Statements relating to future net sales, costs of sales, other expenses, profitability, financial resources, or products and production schedules, or statements that predict or indicate future events and trends and which do not relate solely to historical matters identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's beliefs as well as assumptions made by and information currently available to management. Accordingly, the Company's actual results may differ materially from those expressed or implied in such forward-looking statements due to known and unknown risks and uncertainties that exist in the Company's operations and business environment, including, among other factors, technical risks associated with the development of new products, regulatory policies in the United States and other countries, reimbursement policies of public and private health care payors, introduction and acceptance of new drug therapies, competition from existing products and from new products or technologies, the failure by the Company to produce anticipated cost savings or improve productivity, the timing and magnitude of capital expenditures and acquisitions, currency exchange risks, economic and market conditions in the United States, Europe and the rest of the world, and other risks associated with the Company's operations. The Company disclaims any obligation to update any such factors or to publicly announce any revisions to any of the forward-looking statements contained herein to reflect future events or developments.